Navigation Links
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
Date:9/1/2010

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 1 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140 patients has greater than 90% power to detect differences of analgesic effect, indicating there is no need to enrol additional patients. QRxPharma anticipates completing analysis of this study in Q4 CY2010 and filing a New Drug Application (NDA) for MoxDuo IR in Q1 CY2011.

"It's certainly exciting – as we near completion of our MoxDuo IR clinical program – that interim analysis of the final pivotal study indicates we're on track to obtain significant results," said Dr. John Holaday, Managing Director and CEO. "In study after study this product has performed consistently, successfully achieving every primary end-point. Our emphasis has been to de-risk the MoxDuo IR clinical development program, and these data give us confidence that completion of this study will achieve primary pain relief endpoints and satisfy requirements for NDA filing."

QRxPharma is currently completing its product registration clinical program for MoxDuo IR (a 3:2 ratio of morphine to oxycodone) in the management of moderate to severe acute pain. This comparative study conducted at 10 centres in the US, now well over halfway complete, is evaluating analgesic efficacy and tolerability of a flexible dose regimen (12 mg/8 mg) versus a fixed low dose (3 mg/2 mg) of MoxDuo IR in 140 patients with moderate to severe pain following total knee replacement surgery.

The study design included a blinded interim analysis (70 completed patients) to be conducted by an independent statistician for the purpose of sample size confirmation. This interim analysis indicated that the projected sample size of 140 patients is likely to provide sufficient power to distinguish the
'/>"/>

SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, ... patients can sue drug makers who mislead doctors into believing ... side‑effects.  The case is Weeks v. Wyeth, and the decision ... in that same case last year. Heninger Garrison Davis attorneys ... the patient in the case, Danny Weeks . ...
(Date:8/19/2014)... 2014 Minimally Invasive Devices Inc. (MID), a ... announced today that Mitsubishi Corporation has formally agreed to ... in Japan . MID anticipates that ... Japan in the second half of 2015. ... for Karl Storz GMBH & Co. (endoscopic instruments and ...
(Date:8/19/2014)...  As power morcellator lawsuits continue to mount ... notes that women in need of fibroid removal ... options that do not involve the use of ... report published by The Wall Street Journal on ... mini-laparotomy and vaginal hysterectomy. Non-surgical options for shrinking ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today ... credit facilities of its wholly owned subsidiary Valeant ... by the Company.  The proposed $1.7 billion senior ... a $200 million revolving facility and a $1.5 ...
... 20, 2011 – Ingenuity® Systems, a leading ... life science researchers, today announced the addition ... from miRecords , plus thousands of ... peer-reviewed literature. The newly added content supplements ...
Cached Medicine Technology:Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA 2
(Date:8/19/2014)... Merrick, NY (PRWEB) August 19, 2014 In honor ... helping you care for your old furry friend by offering tips ... to rely on their owners more. Because of this, dog owners ... for them. , As dogs age, their needs change. They will ... outside as much as they used to. Because of this, pet ...
(Date:8/19/2014)... Following the completion of a $16 million rooms ... is proud to debut the highly anticipated final phase of ... revamp of all public spaces to match the fresh look ... all-new dining experience at 1823 Kitchen and Bar and an ... introduction of 1823 Kitchen and Bar, Grand Hyatt Tampa Bay ...
(Date:8/19/2014)... cannot smoke during their stay and could use this time ... stay smoke-free after returning home. Now a study published ... a program that increased the proportion of hospitalized smokers who ... The system used interactive voice response technology automated ... three months after smokers left the hospital. , ...
(Date:8/19/2014)... 2014 Warfarin, the longtime standard treatment for ... in the anticoagulant drug marketplace including dabigatran, rivaroxaban, ... adoption of these novel oral anticoagulants (NOACs) into ... of all new anticoagulant prescriptions yet this represents ... published in The American Journal of Medicine ...
(Date:8/19/2014)... York, New York (PRWEB) August 19, 2014 ... U.S. courts, Bernstein Liebhard LLP notes the publication of ... antipsychotic medications may increase the risk of acute kidney ... by The Ottawa Citizen, the study was conducted by ... Ont., and the Institute for Clinical Evaluative Sciences, and ...
Breaking Medicine News(10 mins):Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
... Grubb & Ellis Healthcare,REIT, Inc. today announced the acquisition ... 5550 South East St., Epler Parke Building B is ... square feet of gross leaseable area., Built in ... offers 196 parking spaces and is accessible by Interstates ...
... Iomai Corporation,(Nasdaq: IOMI ) today announced, ... audit report included in the Company,s Annual,Report on ... Commission on,March 27, 2008 for the fiscal year ... This disclosure is required under NASDAQ,marketplace rules and ...
... ULURU Inc. (Amex:,ULU) today announced that it has scheduled ... results and provide a general business update,on Tuesday, April ... participate in the conference call, please dial (800) 357-0498 ... to ten,minutes prior to the initiation of the teleconference. ...
... Conn., March 28 Darwin,Professional Underwriters, Inc. ... the,resignation of Paul F. Romano, who served ... Thursday, March 27th. Mr. Romano has become,associated ... the,Hartford area., (Logo: http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ...
... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
... With the full House and,Senate poised to ... Relief,(PEPFAR) reauthorization bill, a five-year, $50 billion initiative ... address,the critical HIV prevention shortfalls in the bill., ... to anti-retroviral drugs,(ARVs) since PEPFAR was enacted in ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis 2Health News:Grubb & Ellis Healthcare REIT Acquires Epler Parke Building B in Indianapolis 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4
... The Brasseler USA™ Battery Packs contain ... age have a great impact upon battery ... is necessary. Any deviation from these recommendations ... are sensitive to heat. Any exposure of ...
Pneumatic High-speed Drill, Throttleless, 90k Rpm, Microaire Connector....
Pneumatic foot surgical oscillating saw, 24k cpm, available with various hose connector styles....
... Motor Module, without throttle (MicroAire hose connector). ... attachments., ,1050-100 model requires 10ft. ... MicroAire connector. Also requires 9100-000 Foot Control ... hose 9013-000, or existing hose with Linvatec/Hall ...
Medicine Products: